AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00353145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gemox)
Description: 1000 mg/m\^2, infused at 10 mg/m\^2/min on Day 1 repeated every 14 days (one cycle).
Study NCT00353145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m\^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
Study NCT00353145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Quality of Life Surveys
Study NCT04293783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L.Reuteri
Description: daily supplementation with two tablet for six months
Study NCT04293783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily supplementation with two tablet for six months
Study NCT01928511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly
Study NCT01928511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue therapy
Study NCT01928511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide analogue therapy
Study NCT04596579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Antibody Analysis
Description: 10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
Study NCT04596579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Weck-cel Swab Collection
Description: A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Study NCT01440452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood assessment
Description: If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.
Study NCT02151695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: panretinal photocoagulation
Study NCT02151695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept intravitreal injections
Study NCT01300611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127 300 mcg/kg/day
Description: Injection, 300 mcg/kg/day for 28 days
Study NCT01300611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127 1000 mcg/kg/day
Description: Injection, 1000 mcg/kg/day for 28 days
Study NCT04264819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTH258/Brolucizumab
Description: Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
Study NCT03002480 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thromboelastography-Guided Treatment Regimen
Description: The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate.
Study NCT02822482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
Study NCT02822482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
Study NCT02998541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP640
Description: Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Study NCT02998541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVP-I 0.6%
Description: Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Study NCT02998541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Study NCT02149394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice popsicle
Description: Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.
Study NCT02149394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water at room temperature
Description: Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
Study NCT03944161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutrition supplement
Description: Hypercaloric and high protein supplement
Study NCT03944161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional advice
Description: Advice given by the clinician
Study NCT00396370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1 mL of sterile Sauton medium for intradermal administration.
Study NCT00396370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 60 mL of sterile phosphate buffered saline (PBS) for oral administration.
Study NCT03708510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorative materials- Filtek Silorane
Description: Filtek Silorane
Study NCT03708510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorative materials-Kalore
Description: Kalore
Study NCT03708510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preparation-Er,Cr:YSGG Laser
Description: Er,Cr:YSGG Laser
Study NCT03708510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preparation- Diamond Bur
Description: Bur
Study NCT02073201 — intervention group
Intervention type: OTHER
Intervention: High-functioning older adults
Description: Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
Study NCT02073201 — intervention group
Intervention type: OTHER
Intervention: Lower-functioning older adults
Description: Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
Study NCT02073201 — intervention group
Intervention type: OTHER
Intervention: Young adults
Description: Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
Study NCT03511287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
Study NCT03944161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional advice
Description: Advice given by the clinician
Study NCT04012931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
Study NCT04012931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV Background Regimen
Description: The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
Study NCT05657431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: essential oils (Ylang ylang oil)
Description: inhaler aromatherapy
Study NCT03667859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal Tactile Imaging
Description: Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
Study NCT05657431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline solutions)
Description: placebo saline solutions
Study NCT05657431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: essential oils (lemon oil)
Description: inhaler aromatherapy
Study NCT02356315 — intervention group
Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Description: Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
Study NCT04087304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Status Optimization
Description: Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
Study NCT02068027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Gel 0.1%
Study NCT02068027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01704521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegInterferon
Study NCT01704521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT01704521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Study NCT01863420 — intervention group
Intervention type: RADIATION
Intervention: Bone Marrow-sparing Intensity-Modulated Radiotherapy
Description: Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
Study NCT00335478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm\^3.
Study NCT02173873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept drug
Description: intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
Study NCT01032174 — intervention group
Intervention type: DRUG
Intervention: Azithromycin SR
Description: Azithromycin SR, 2.0 g by mouth (PO) x 1
Study NCT01032174 — intervention group
Intervention type: DRUG
Intervention: Amoxiclav 1000 mg
Description: Amoxiclav 1000 mg x twice daily, 10 days
Study NCT01837407 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Composite Flap
Description: nerve transfer with the dorsal branch of the digital nerve
Study NCT04550910 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Hypofractionation Schedules for Breast Cancer patients after mastecomy
Description: Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
Study NCT04550910 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation Schedules for Breast Cancer patients after mastecomy
Description: Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
Study NCT02932423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control product E
Description: Plain water
Study NCT02932423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product A
Description: Beverage with no sugar but sweetener
Study NCT02932423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product B
Description: Beverage with 22 g/L sugar and sweetener
Study NCT03658148 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Surgery with Cardiopulmonary Bypass
Description: Cardiac Surgery with Cardiopulmonary Bypass
Study NCT02568280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
Study NCT02568280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
Study NCT01350596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alivium®
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
Study NCT01350596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
Study NCT04229914 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: stroke patinets
Description: 3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
Study NCT00820599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapien XT™ transcatheter heart valve and delivery system
Study NCT04596579 — intervention group
Intervention type: BEHAVIORAL
Intervention: Web Based Questionnaire
Description: A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Study NCT01282775 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WEB + Environment
Description: Participants receive weekly lessons via the Web along with additional tools for weight loss support
Study NCT01282775 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WEB + Cash Incentive for Weight Loss
Description: Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
Study NCT01134575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMC-544 (Inotuzumab Ozogamycin)
Description: First patients > 16 years and \< 16 years receive CMC-544 at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
Study NCT01134575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
Study NCT06096129 — intervention group
Intervention type: PROCEDURE
Intervention: Spy PTC
Description: Percutaneous transhepatic cholangioscopy with SpyGlass DS system
Study NCT03078920 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Naída CROS
Description: At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
Study NCT01735929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck Liposuction and Ultrasound Treatment
Study NCT01735929 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Study NCT01112072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
Study NCT01101919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
Study NCT04463264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
Study NCT04463264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
Study NCT00906698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 low (20mg) dosage
Description: Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
Study NCT00906698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 medium (40mg) dosage
Description: Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
Study NCT00906698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 high (50mg) dosage
Description: Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
Study NCT00906698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine per os 60 mg/m²
Description: Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
Study NCT00906698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine per os 80 mg/m²
Description: Patients will receive 80 mg/m² Vinorelbine per os at J22
Study NCT00906698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine i.v. 25 mg/m²
Description: Patients will receive 25 mg/m² of Vinorelbine i.v.
Study NCT05288101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proteinex and Enterex DBT Victus Laboratories
Description: The supplement was provided five days per week. Three days a week, the supplement was given at the beginning of the HD session and the patients were instructed to consume it slowly during the next 3 hours. The remaining two days, the supplement was consumed at home and instructed to be consumed between meals. The ONS consisted of one can of polymeric formula (Enterex DBT, Victus Laboratories) and 5.6 g of a protein powder supplement (Proteinex, Victus Laboratories). The final mixture provided 240 kcal, 17 g protein, 8.1 g lipids, 25 g carbohydrates, 4 g dietary fiber, 201 mg sodium, 490 mg calcium, 356 mg phosphorus and 371 mg potassium
Study NCT05288101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry weight adjustment through BIVA
Description: Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.
Study NCT05288101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry weight adjustment through BIVA
Description: Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.